Know Cancer

forgot password

Randomized Phase II Study of Adriamycin/Cytoxan/Taxol (ACT) vs. Cytoxan, Thiotepa, Carboplatin (STAMP V) in Patients With High-Risk Primary Breast Cancer

Phase 2
60 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

Randomized Phase II Study of Adriamycin/Cytoxan/Taxol (ACT) vs. Cytoxan, Thiotepa, Carboplatin (STAMP V) in Patients With High-Risk Primary Breast Cancer


- Compare the toxic effects of doxorubicin, cyclophosphamide, and paclitaxel vs
cyclophosphamide, thiotepa, and carboplatin in patients with high-risk primary breast
cancer. (Arm I closed to accural as of 4/6/2006.)

- Compare the efficacies of these regimens followed by peripheral blood stem cell rescue
in these patients.

- Determine the efficacy of a bisphosphonate to prevent relapse/metastasis after
high-dose chemotherapy in these patients.

OUTLINE: This is a randomized study. Patients are stratified by stage of disease.

Peripheral blood stem cells (PBSC) are collected after mobilization with filgrastim (G-CSF),
administered subcutaneously or IV, twice daily beginning 3 days before collection and
continuing until collection is complete.

All patients receive conventional-dose adjuvant chemotherapy, probably comprising
doxorubicin IV, cyclophosphamide IV, and fluorouracil IV over 1 hour on days 1, 22, 43, and
64. Patients are then randomized to receive 1 of 2 treatment arms of high-dose chemotherapy.
(Arm I closed to accrual as of 4/6/2006.)

- Arm I (ACT) (closed to accrual as of 4/6/2006): Patients receive doxorubicin IV over 24
hours on days -9 to -6, cyclophosphamide IV over 2 hours on day -5, and paclitaxel IV
over 24 hours on day -2. PBSC are reinfused on days -2 and 0. G-CSF is administered
beginning on day 0 and continuing until blood counts recover.

- Arm II (STAMP V): Patients receive cyclophosphamide IV, carboplatin IV, and thiotepa IV
over 24 hours on days -7 to -4. PBSC are reinfused and G-CSF is administered as in arm

Within 4-6 weeks of day 0 of high-dose chemotherapy, patients with estrogen and/or
progesterone receptor positive tumors receive oral tamoxifen twice daily for 5 years.
Patients are also randomized to receive a bisphosphonate comprising pamidronate IV every 4
weeks for 2 years.

Quality of life is assessed before therapy, at 30 days after high-dose chemotherapy, and at
6 and 12 months.

Patients are followed every 3 months for 1 year and then every 6 months for at least 10

PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 3 years.

Inclusion Criteria


- Histologically proven high-risk primary breast cancer with less than 60% chance of
progression-free survival of 3 years from diagnosis

- Stage II with at least 10 positive axillary nodes OR

- Stage IIIA or IIIB

- No histologically proven bone marrow metastasis

- No CNS metastasis

- Hormone receptor status:

- Hormone receptor status known



- Physiological age 60 or under

Menopausal status:

- Not specified

Performance status:

- Karnofsky 80-100%

Life expectancy:

- See Disease Characteristics


- Neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3


- Bilirubin no greater than 1.5 mg/dL

- SGOT or SGPT no greater than 2 times upper limit of normal

- Hepatitis B antigen negative


- Creatinine no greater than 1.2 mg/dL

- Creatinine clearance at least 70 mL/min

- No prior hemorrhagic cystitis


- Ejection fraction at least 55% by MUGA

- No prior significant valvular heart disease or arrhythmia


- FEV_1 at least 60% of predicted

- pO_2 at least 85 mm Hg on room air

- pCO_2 at least 43 mm Hg on room air

- DLCO at least 60% lower limit of predicted


- No other prior malignancy except squamous cell or basal cell skin cancer or stage I
or carcinoma in situ of the cervix

- No CNS dysfunction that would preclude compliance

- HIV negative

- No sensitivity to E. coli-derived products

- Not pregnant

- Fertile patients must use effective contraception


Biologic therapy:

- Not specified


- At least 4 weeks since prior chemotherapy

- No prior doxorubicin of total dose exceeding 240 mg/m^2

- No prior paclitaxel of total dose of at least 750 mg/m^2

- No more than 12 months since prior conventional-dose adjuvant chemotherapy

Endocrine therapy:

- At least 4 weeks since prior hormonal therapy


- At least 4 weeks since prior radiotherapy

- No prior radiation to the left chest wall


- Not specified

Type of Study:


Study Design:

Allocation: Randomized, Primary Purpose: Treatment

Outcome Measure:

Disease-free survival

Safety Issue:


Principal Investigator

George Somlo, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

City of Hope Medical Center


United States: Federal Government

Study ID:




Start Date:

May 1999

Completion Date:

Related Keywords:

  • Breast Cancer
  • stage II breast cancer
  • stage IIIA breast cancer
  • stage IIIB breast cancer
  • Breast Neoplasms



City of Hope Comprehensive Cancer Center Duarte, California  91010
Banner Good Samaritan Medical Center Phoenix, Arizona  85006